The coronavirus pandemic has placed unprecedented burdens on cord blood and perinatal tissue investigations, but it has not sent those studies into quarantine. That’s immediately evident when scanning the agenda for this year’s Cord Blood Connect international congress.
Resourceful investigators have been pushing forward on their clinical trials and laboratory studies. They will be bringing results and status reports to the virtual congress that is scheduled for two consecutive Thursdays, Sept. 10 and 17.
“We are thrilled to bring to congress attendees a scientific program that is relevant to all that is happening in 2020 and beyond,” said Ngaire Elwood, PhD, chair of the Scientific Program Committee. “There will be plenty of opportunity for interaction and discussion on the topics presented, with moderated Q&A time at the end of each session.”
The morning of the first day includes back-to-back sessions presenting the state of cord blood transplantation. The first of those sessions will be an update on the latest advances, and the second will focus on innovations. The second day, a week later, leads off with a session on COVID-19, both how cord blood banks are coping with the pandemic, and investigations of the use of cord blood in treatment.
Accepted abstracts will be presented in the form of “e-posters” that can be accessed on demand. The complete agenda of sessions can be accessed online.
Registration for the congress includes the two days of webcasts and unlimited access to all congress components for 12 months. All sessions, e-posters and virtual exhibits will be recorded and remain available to registrants through August next year.
The registration fee, $120, is waived for CBA members who register by Aug. 31. If you aren’t a CBA member, or your membership has lapsed, you can join or renew when registering and the congress fee will be waived. CBA individual member annual dues are $99 USD.